Polyvalent DNA Vaccines Expressing HA Antigens of H5N1 Influenza Viruses with an Optimized Leader Sequence Elicit Cross-protective Antibody Responses

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Dec 30

PMID 22205966

Citations 20

Authors

Shixia Wang

Anthony Hackett

Na Jia

Chunhua Zhang

Lu Zhang

Chris Parker

An Zhou

Jun Li

Wu-Chun Cao

Zuhu Huang

Yan Li

Shan Lu

Affiliations

Soon will be listed here.

Abstract

Highly pathogenic avian influenza A (HPAI) H5N1 viruses are circulating among poultry populations in parts of Asia, Africa, and the Middle East, and have caused human infections with a high mortality rate. H5 subtype hemagglutinin (HA) has evolved into phylogenetically distinct clades and subclades based on viruses isolated from various avian species. Since 1997, humans have been infected by HPAI H5N1 viruses from several clades. It is, therefore, important to develop strategies to produce protective antibody responses against H5N1 viruses from multiple clades or antigenic groups. In the current study, we optimized the signal peptide design of DNA vaccines expressing HA antigens from H5N1 viruses. Cross reactivity analysis using sera from immunized rabbits showed that antibody responses elicited by a polyvalent formulation, including HA antigens from different clades, was able to elicit broad protective antibody responses against multiple key representative H5N1 viruses across different clades. Data presented in this report support the development of a polyvalent DNA vaccine strategy against the threat of a potential H5N1 influenza pandemic.

Citing Articles

Development of Universal Influenza Vaccines Targeting Conserved Viral Proteins.

Jazayeri S, Poh C Vaccines (Basel). 2019; 7(4).

PMID: 31683888 PMC: 6963725. DOI: 10.3390/vaccines7040169.

A Review of DNA Vaccines Against Influenza.

Lee L, Izzard L, Hurt A Front Immunol. 2018; 9:1568.

PMID: 30038621 PMC: 6046547. DOI: 10.3389/fimmu.2018.01568.

Novel Platforms for the Development of a Universal Influenza Vaccine.

Kumar A, Sundebo Meldgaard T, Bertholet S Front Immunol. 2018; 9:600.

PMID: 29628926 PMC: 5877485. DOI: 10.3389/fimmu.2018.00600.

Codon-Optimized P1A-Encoding DNA Vaccine: Toward a Therapeutic Vaccination against P815 Mastocytoma.

Lopes A, Vanvarenberg K, Preat V, Vandermeulen G Mol Ther Nucleic Acids. 2017; 8:404-415.

PMID: 28918040 PMC: 5537203. DOI: 10.1016/j.omtn.2017.07.011.

A polyvalent influenza DNA vaccine applied by needle-free intradermal delivery induces cross-reactive humoral and cellular immune responses in pigs.

Borggren M, Nielsen J, Karlsson I, Dalgaard T, Trebbien R, Williams J Vaccine. 2016; 34(32):3634-40.

PMID: 27211039 PMC: 4940207. DOI: 10.1016/j.vaccine.2016.05.030.

References

Wu W, Chen Y, Wang P, Song W, Lau S, Rayner J . Antigenic profile of avian H5N1 viruses in Asia from 2002 to 2007. J Virol. 2007; 82(4):1798-807. PMC: 2258718. DOI: 10.1128/JVI.02256-07. View

Wang S, Joshi S, Lu S . Delivery of DNA to skin by particle bombardment. Methods Mol Biol. 2004; 245:185-96. DOI: 10.1385/1-59259-649-5:185. View

DuBridge R, Tang P, Hsia H, Leong P, Miller J, Calos M . Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol. 1987; 7(1):379-87. PMC: 365079. DOI: 10.1128/mcb.7.1.379-387.1987. View

Kong W, Hood C, Yang Z, Wei C, Xu L, Garcia-Sastre A . Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc Natl Acad Sci U S A. 2006; 103(43):15987-91. PMC: 1613227. DOI: 10.1073/pnas.0607564103. View

Li C, Ping J, Jing B, Deng G, Jiang Y, Li Y . H5N1 influenza marker vaccine for serological differentiation between vaccinated and infected chickens. Biochem Biophys Res Commun. 2008; 372(2):293-7. DOI: 10.1016/j.bbrc.2008.05.057. View

Nyoman Kandun I, Wibisono H, Sedyaningsih E, Yusharmen , Hadisoedarsuno W, Purba W . Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med. 2006; 355(21):2186-94. DOI: 10.1056/NEJMoa060930. View

Abdel-Ghafar A, Chotpitayasunondh T, Gao Z, Hayden F, Nguyen D, de Jong M . Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008; 358(3):261-73. DOI: 10.1056/NEJMra0707279. View

Suguitan Jr A, McAuliffe J, Mills K, Jin H, Duke G, Lu B . Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med. 2006; 3(9):e360. PMC: 1564176. DOI: 10.1371/journal.pmed.0030360. View

Chen H, Smith G, Zhang S, Qin K, Wang J, Li K . Avian flu: H5N1 virus outbreak in migratory waterfowl. Nature. 2005; 436(7048):191-2. DOI: 10.1038/nature03974. View

10.

Salomon R, Franks J, Govorkova E, Ilyushina N, Yen H, Hulse-Post D . The polymerase complex genes contribute to the high virulence of the human H5N1 influenza virus isolate A/Vietnam/1203/04. J Exp Med. 2006; 203(3):689-97. PMC: 2118237. DOI: 10.1084/jem.20051938. View

11.

Wang S, Joshi S, Mboudjeka I, Liu F, Ling T, Goguen J . Relative immunogenicity and protection potential of candidate Yersinia Pestis antigens against lethal mucosal plague challenge in Balb/C mice. Vaccine. 2008; 26(13):1664-74. PMC: 2288748. DOI: 10.1016/j.vaccine.2008.01.024. View

12.

Wang S, Chou T, Sakhatskyy P, Huang S, Lawrence J, Cao H . Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system. J Virol. 2005; 79(3):1906-10. PMC: 544123. DOI: 10.1128/JVI.79.3.1906-1910.2005. View

13.

Bresson J, Perronne C, Launay O, Gerdil C, Saville M, Wood J . Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet. 2006; 367(9523):1657-64. DOI: 10.1016/S0140-6736(06)68656-X. View

14.

Tarentino A, Gomez C, PLUMMER Jr T . Deglycosylation of asparagine-linked glycans by peptide:N-glycosidase F. Biochemistry. 1985; 24(17):4665-71. DOI: 10.1021/bi00338a028. View

15.

Lin J, Zhang J, Dong X, Fang H, Chen J, Su N . Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet. 2006; 368(9540):991-7. DOI: 10.1016/S0140-6736(06)69294-5. View

16.

Wang S, Zhang C, Zhang L, Li J, Huang Z, Lu S . The relative immunogenicity of DNA vaccines delivered by the intramuscular needle injection, electroporation and gene gun methods. Vaccine. 2008; 26(17):2100-10. PMC: 2790191. DOI: 10.1016/j.vaccine.2008.02.033. View

17.

Tobita K . Permanent canine kidney (MDCK) cells for isolation and plaque assay of influenza B viruses. Med Microbiol Immunol. 1975; 162(1):23-7. DOI: 10.1007/BF02123574. View

18.

Hoffmann E, Lipatov A, Webby R, Govorkova E, Webster R . Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci U S A. 2005; 102(36):12915-20. PMC: 1200312. DOI: 10.1073/pnas.0506416102. View

19.

Bornholdt Z, Prasad B . X-ray structure of NS1 from a highly pathogenic H5N1 influenza virus. Nature. 2008; 456(7224):985-8. PMC: 2798118. DOI: 10.1038/nature07444. View

20.

Shu Y, Yu H, Li D . Lethal avian influenza A (H5N1) infection in a pregnant woman in Anhui Province, China. N Engl J Med. 2006; 354(13):1421-2. DOI: 10.1056/NEJMc053524. View